The world of pediatric vaccines is about to be shaken. And it's Hyderabad based Shantha Biotech that's going to do all the shaking
The world of pediatric vaccines is about to be shaken. And it's Hyderabad-based Shantha Biotech that's going to do all the shaking, reports CNBC-TV18's Appaji Reddem and Animesh Das.
Offices belonging to Hyderabad-based Shanta Biotech look calm from the outside, but inside, plans are brewing to take the pediatric vaccine market by storm. This Sanofi-Aventis-owned drug manufacturer is all set to launch Pentavalent, a single vaccine aimed at protecting children from five illnesses- Diphtheria, Pertussis, Tetanus, Hepatitis B and Haemophilus Influenzae. This launch will bring global prices for the vaccine down drastically.
Harish V Iyer, managing director and chief executive officer of Shantha Biotech says, "One assumption you have to make in this market unfortunately is that the prices may come down. We are thinking in those lines and I don't want to speculate on where the prices would end up."
This will be the second time Shanta Biotech launches this vaccine.
"25 million children are born every year," says Iyer. "If you assume three doses, 75 million is the opportunity in India every year. Depending upon the rates of coverage and how thing work out, it could be somewhere in the range of 25-50 million at least if you assume 50% penetration," he says.
Shanta Biotech will invest over USD 300 million on a vaccine manufacturing facility at Hyderabad to supplement vaccine production.
Government of India had included Pentavalent in its universal immunization program in Kerala and Tamil Nadu last December. The vaccine is expected to be extended to six more states. However, regulatory approvals, safety concerns and pricing will be the major challenges.
READ MORE ON Shantha Biotech, pediatric, vaccine, Sanofi-Aventis, Pentavalent, Diphtheria, Pertussis, Tetanus, Hepatitis B, Haemophilus Influenzae, WHO, Serum Institute, Panacea Biotec, Kerala, Tamil Nadu
ADS BY GOOGLE
video of the day
Short-term players, beware of Greece: Religare Invesco MF